Omnicell (OMCL) Misses Q2 EPS by 2c; Maintains Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Omnicell Announces Financial Results for Second Quarter 2022
August 4, 2022 4:01 PM EDTGAAP revenues of $331 million and non-GAAP revenues of $332 million
GAAP net income per diluted share of $0.20
Non-GAAP net income per diluted share of $0.84
Second quarter results reflect an impact from the previously disclosed ransomware incident; full year 2022 outlook is unchanged
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (Omnicell, we, our, us, management, or the Company), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its second quarter ended June 30,... More
